Hidradenitis suppurativa - current and promising non-surgical treatment
DOI:
https://doi.org/10.12775/JEHS.2023.26.01.012Keywords
hidradenitis suppurativa, Acne inversa, treatement, management, biologicAbstract
Introduction and purpose: Hidradenitis suppurativa (HS) also known as acne inversa is a chronic, inflammatory dermatosis with predilection to apocrine gland-rich regions. It is a multifactorial disease in which genetic and environmental factors play a key role. In this paper, we provide an overview of the current knowledge in most commonly used and emerging treatment options of HS.
A brief description of the state of knowledge: The primary defect in HS pathophysiology involves follicular hyperkeratosis with occlusion of the pilosebaceous apparatus, followed by follicular rupture and immune responses. It typically develops after puberty with deep-seated painful nodules, abscesses, sinus tracts and scars. Due to the permanently painful, odorous lesions, hidradenitis suppurativa is one of the most distressing dermatological diseases with a substantial impact on patients’ quality of life. Inflammation in patients with HS is not limited to the skin but is systemic. Patients with HS frequently have significant comorbidities like metabolic syndrome, type 2 diabetes mellitus, spondyloarthropathy, inflammatory bowel disease and depression. Treatment is challenging and consists of pharmacological and surgical techniques, which must often be combined for best results.
Materials and methods: A search was conducted using PubMed and GoogleScholar data bases. Articles were searched in English using the following key words: “hidradenitis suppurativa”, “acne invera”, “treatement”, “management”, “biological treatement”.
Summary: Therapeutic options have rapidly evolved in the last decade and include the use of topical therapies, systemic antibiotics and a wide range of immunosuppressive medications such as anti-TNF-α biologics, but the number of therapies approved for HS is limited.
References
Jemec GB, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S4-7. doi: 10.1016/j.jaad.2015.07.052. PMID: 26470614.
Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020 Mar 12;6(1):18. doi: 10.1038/s41572-020-0149-1. PMID: 32165620.
Ingram JR. The Genetics of Hidradenitis Suppurativa. Dermatol Clin. 2016 Jan;34(1):23-8. doi: 10.1016/j.det.2015.07.002. PMID: 26617354.
Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System. Dermatology. 2020;236:421–430.
Miller IM, McAndrew RJ, Hamzavi I. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa. Dermatol Clin. 2016 Jan;34(1):7-16. doi: 10.1016/j.det.2015.08.002. PMID: 26617352.
Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, Philipp S, Uribe D, Wolk K, Sterry W. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7(2):e31810. doi: 10.1371/journal.pone.0031810. Epub 2012 Feb 16. PMID: 22359634; PMCID: PMC3281019.
Richette P, Molto A, Viguier M, Dawidowicz K, Hayem G, Nassif A, Wendling D, Aubin F, Lioté F, Bachelez H. Hidradenitis suppurativa associated with spondyloarthritis -- results from a multicenter national prospective study. J Rheumatol. 2014 Mar;41(3):490-4. doi: 10.3899/jrheum.130977. Epub 2014 Jan 15. PMID: 24429166.
Sadowska M , Lesiak A , Narbutt J. Choroby współistniejące z hidradenitis suppurativa. Forum Dermatologicum 2019, tom 5, nr 4, 112–116 DOI: 10.5603/FD.2019.0011
Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017 Nov 28;318(20):2019-2032. doi: 10.1001/jama.2017.16691. PMID: 29183082.
Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009 Sep;23(9):985-98. doi: 10.1111/j.1468-3083.2009.03356.x. PMID: 19682181.
Danesh MJ, Kimball AB. Pyrithione zinc as a general management strategy for hidradenitis suppurativa. J Am Acad Dermatol. 2015 Nov;73(5):e175. doi: 10.1016/j.jaad.2015.07.026. PMID: 26475559.
Alavi A, Kirsner RS. Local wound care and topical management of hidradenitis suppurativa. J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S55-61. doi: 10.1016/j.jaad.2015.07.048. PMID: 26470618.
Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983 Jun;22(5):325-8. doi: 10.1111/j.1365-4362.1983.tb02150.x. PMID: 6347922.
Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998 Dec;39(6):971-4. doi: 10.1016/s0190-9622(98)70272-5. PMID: 9843011.)
Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, Hamzavi I. Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice. Dermatology. 2020;236(5):393-412. doi: 10.1159/000507323. Epub 2020 May 14. PMID: 32408306; PMCID: PMC8177083.
Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998 Dec;39(6):971-4. doi: 10.1016/s0190-9622(98)70272-5. PMID: 9843011.
Schneller-Pavelescu L, Vergara-de Caso E, Martorell A, Romaní J, Lázaro M, Vilarrasa E, Díaz-Ley B, Vázquez-Osorio I, Segura Palacios JM, Azaña JM, González-López MA, Cañueto J, Molina-Leyva A, Leiva-Salinas M, Navarro-Triviño FJ, Sánchez-Payá J, Pascual JC. Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes. J Am Acad Dermatol. 2019 May;80(5):1455-1457. doi: 10.1016/j.jaad.2018.12.043. Epub 2019 Jan 8. PMID: 30630028
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101. doi: 10.1016/j.jaad.2019.02.068. Epub 2019 Mar 11. PMID: 30872149; PMCID: PMC9131892.
Mendes-Bastos P, Macedo R, Duarte R. Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis? Br J Dermatol. 2017 Oct;177(4):e150-e151. doi: 10.1111/bjd.15500. Epub 2017 Sep 27. PMID: 28718933.
Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1101-8. doi: 10.1111/j.1468-3083.2012.04668.x. Epub 2012 Aug 11. PMID: 22882365.
Davis SA, Lin HC, Balkrishnan R, Feldman SR. Hidradenitis Suppurativa Management in the United States: An Analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases. Skin Appendage Disord. 2015 Sep;1(2):65-73. doi: 10.1159/000431037. Epub 2015 Jun 20. PMID: 27172455; PMCID: PMC4857854.
Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, Hamzavi I. Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice. Dermatology. 2020;236(5):393-412. doi: 10.1159/000507323. Epub 2020 May 14. PMID: 32408306; PMCID: PMC8177083.
Ortiz NE, Nijhawan RI, Weinberg JM. Acitretin. Dermatol Ther. 2013 Sep-Oct;26(5):390-9. doi: 10.1111/dth.12086. PMID: 24099069.
Maarouf M, Clark AK, Lee DE, Shi VY. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018 Aug;29(5):441-449. doi: 10.1080/09546634.2017.1395806. Epub 2017 Nov 10. PMID: 29098911.
Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370. PMID: 27518661
Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019 Jan;80(1):60-69.e2. doi: 10.1016/j.jaad.2018.05.040. Epub 2018 Jun 1. PMID: 29860040.
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101. doi: 10.1016/j.jaad.2019.02.068. Epub 2019 Mar 11. PMID: 30872149; PMCID: PMC9131892.
Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010 Feb;62(2):205-17. doi: 10.1016/j.jaad.2009.06.050. PMID: 20115947.
Paradela S, Rodríguez-Lojo R, Fernández-Torres R, Arévalo P, Fonseca E. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat. 2012 Aug;23(4):278-83. doi: 10.3109/09546634.2012.683767. Epub 2012 Jun 5. PMID: 22482700.
Lesage C, Adnot-Desanlis L, Perceau G, Bonnet M, Palot JP, Bernard P, Reguiaï Z. Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa. Eur J Dermatol. 2012 Sep-Oct;22(5):640-4. doi: 10.1684/ejd.2012.1795. PMID: 22759562.
Yao Y, Thomsen SF. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa. Dermatol Online J. 2017 Jul 15;23(7):13030/qt8rw2j9zv. PMID: 29469692.
Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018 Jul;179(1):182-185. doi: 10.1111/bjd.15769. Epub 2018 Mar 25. PMID: 28654150.
Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab. Acta Derm Venereol. 2018 Jan 12;98(1):151-152. doi: 10.2340/00015555-2794. PMID: 28902952.
Jørgensen AR, Yao Y, Thomsen SF. Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa. Case Rep Dermatol Med. 2018 Apr 16;2018:8685136. doi: 10.1155/2018/8685136. PMID: 29850284; PMCID: PMC5926496.
Głowaczewska A, Szepietowski JC, Matusiak Ł. Severe hidradenitis suppurativa successfully treated with secukinumab. Dermatol Ther. 2020 Nov;33(6):e13845. doi: 10.1111/dth.13845. Epub 2020 Jul 5. PMID: 32544258.
Villegas-Romero I, Collantes-Rodríguez C, Valenzuela-Ubiña S, Jiménez-Gallo D. Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab. Actas Dermosifiliogr (Engl Ed). 2020 Oct;111(8):696-698. English, Spanish. doi: 10.1016/j.ad.2019.07.007. Epub 2020 Jun 15. PMID: 32553985.
Chiricozzi A, Garcovich S, Malvaso D, Giovanardi G, Peris K. COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus. Int J Dermatol. 2020 Nov;59(11):1423-1424. doi: 10.1111/ijd.15209. Epub 2020 Sep 23. PMID: 32966593; PMCID: PMC7536954.
Prussick L, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Abdat R, Alomran A, Zancanaro P, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12. PMID: 30801662.
Casseres RG, Prussick L, Zancanaro P, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Au SC, Alomran A, Abdat R, Abudu M, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. J Am Acad Dermatol. 2020 Jun;82(6):1524-1526. doi: 10.1016/j.jaad.2020.02.005. Epub 2020 Feb 7. PMID: 32044410.
Reguiaï Z, Fougerousse AC, Maccari F, Bécherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e750-e751. doi: 10.1111/jdv.16605. Epub 2020 Jun 8. PMID: 32401354.
Ribero S, Ramondetta A, Fabbrocini G, Bettoli V, Potenza C, Chiricozzi A, Licciardello M, Marzano AV, Bianchi L, Rozzo G, Fania L, Marasca C, Odorici G, Mambrin A, Moltrasio C, Caposiena Caro RD, Skroza N, Quaglino P, Siliquini N, Dapavo P. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e441-e442. doi: 10.1111/jdv.17178. Epub 2021 Mar 9. PMID: 33594790.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023 Feb 3;S0140-6736(23)00022-3. doi: 10.1016/S0140-6736(23)00022-3
Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis (Auckl). 2022 Jun 8;12:127-137. doi: 10.2147/PTT.S367744. PMID: 35707807; PMCID: PMC9189155.
Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, Harari OA, Lambert J, Shaw S. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017 May;83(5):991-1001. doi: 10.1111/bcp.13185. Epub 2017 Jan 10. PMID: 27859546; PMCID: PMC5401985.
Bimekizumab - prescribing information. Available from: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf Accessed May 11, 2023.
ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I). Available at: https://clinicaltrials.gov/ct2/show/NCT04242446?term=be+heard&draw=2&rank=1. Last accessed: March 2023 5.
ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II). Available at: https://clinicaltrials.gov/ct2/show/NCT04242498 Last accessed: March 2023
Kimball AB, Zouboulis CC, Sayed C, et al. Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo controlled, multicenter studies. Presented at Late-breaking Research Session 1 of the Annual Academy of Dermatology Annual Meeting. March 17-21, 2023; New Orleans, LA.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Natalia Baran, Klaudia Bogusz, Marcela Maksymowicz, Adriana Bielak, Aleksandra Nowak, Łucja Cywka, Weronika Szwed, Alicja Nowak, Piotr Machowiec
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 370
Number of citations: 0